Effects of pioglitazone on serum fetuin-A levels in patients with type 2 diabetes mellitus

Metabolism: Clinical and Experimental

Volumn 57, Issue 9, 2008, Pages 1248-1252

  Mori, Katsuhito ^a   Emoto, Masanori ^a   Araki, Takahiro ^a   Yokoyama, Hisayo ^a   Lee, Eiko ^a   Teramura, Megumi ^a   Koyama, Hidenori ^a   Shoji, Tetsuo ^a   Inaba, Masaaki ^a   Nishizawa, Yoshiki ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FETUIN A; HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE;

ADULT; AEROBIC EXERCISE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; INSULIN RESISTANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; TREATMENT DURATION;

AGED; BLOOD PROTEINS; DIABETES MELLITUS, TYPE 2; EXERCISE; EXERCISE THERAPY; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; METFORMIN; MIDDLE AGED; THIAZOLIDINEDIONES;

EID: 48849102707     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2008.04.019     Document Type: Article

References (20)

1. Kahn B.B., Alquier T., Carling D., and Hardie D.G. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1 (2005) 15-25
2. Auberger P., Falquerho L., Contreres J.O., et al. Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity. Cell 58 (1989) 631-640
3. Srinivas P.R., Wagner A.S., Reddy L.V., et al. Serum alpha 2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level. Mol Endocrinol 7 (1993) 1445-1455
4. Kalabay L., Chavin K., Lebreton J.P., et al. Human recombinant alpha 2-HS glycoprotein is produced in insect cells as a full length inhibitor of the insulin receptor tyrosine kinase. Horm Metab Res 30 (1998) 1-6
5. Mathews S.T., Chellam N., Srinivas P.R., et al. Alpha2-HSG, a specific inhibitor of insulin receptor autophosphorylation, interacts with the insulin receptor. Mol Cell Endocrinol 164 (2000) 87-98
6. Mathews S.T., Singh G.P., Ranalletta M., et al. Improved insulin sensitivity and resistance to weight gain in mice null for the Ahsg gene. Diabetes 51 (2002) 2450-2458
7. Mathews S.T., Rakhade S., Zhou X., et al. Fetuin-null mice are protected against obesity and insulin resistance associated with aging. Biochem Biophys Res Commun 350 (2006) 437-443
8. Mori K., Emoto M., Yokoyama H., et al. Association of serum fetuin-A with insulin resistance in type 2 diabetic and nondiabetic subjects. Diabetes Care 29 (2006) 468
9. Stefan N., Hennige A.M., Staiger H., et al. Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care 29 (2006) 853-857
10. Ix J.H., Shlipak M.G., Brandenburg V.M., et al. Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation 113 (2006) 1760-1767
11. Wasserman K., Whipp B.J., Koyl S.N., et al. Anaerobic threshold and respiratory gas exchange during exercise. J Appl Physiol 35 (1973) 236-243
12. Mori K., Emoto M., Araki T., et al. Association of serum fetuin-A with carotid arterial stiffness. Clin Endocrinol (Oxf) 66 (2007) 246-250
13. Roden M. Mechanisms of disease: hepatic steatosis in type 2 diabetes-pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab 2 (2006) 335-348
14. Belfort R., Harrison S.A., Brown K., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355 (2006) 2297-2307
15. Kadowaki T., Yamauchi T., Kubota N., et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116 (2006) 1784-1792
16. Pfutzner A., Marx N., Lubben G., et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 45 (2005) 1925-1931
17. Mazzone T., Meyer P.M., Feinstein S.B., et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 296 (2006) 2572-2581
18. Fiore C.E., Celotta G., Politi G.G., et al. Association of high alpha(2)-Heremans-Schmid glycoprotein/fetuin concentration in serum and intima-media thickness in patients with atherosclerotic vascular disease and low bone mass. Atherosclerosis 195 (2007) 110-115
19. Ketteler M., Bongartz P., Westenfeld R., et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 361 (2003) 827-833
20. Ketteler M. Fetuin-A and extraosseous calcification in uremia. Curr Opin Nephrol Hypertens 14 (2005) 337-342